Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 10;39(17):1947-1948.
doi: 10.1200/JCO.21.00424. Epub 2021 Apr 1.

Reply to K. Ando et al

Joseph A Sparano  1 , Michael R Crager  1 , Gong Tang  1 , Robert J Gray  1 , Salomon M Stemmer  1 , Steven Shak  1
Affiliations
Comment

Reply to K. Ando et al

Joseph A Sparano et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Joseph A. SparanoStock and Other Ownership Interests: MetastatConsulting or Advisory Role: Genentech/Roche, Novartis, AstraZeneca, Celgene, Lilly, Celldex, Pfizer, Prescient Therapeutics, Juno Therapeutics, Merrimack, Adgero Biopharmaceuticals, Cardinal Health, GlaxoSmithKline, CStone Pharmaceuticals, Epic Sciences, Daiichi SankyoResearch Funding: Prescient Therapeutics, Deciphera, Genentech/Roche, Merck, Novartis, Merrimack, Radius HealthTravel, Accommodations, Expenses: Menarini Silicon Biosystems, Roche/Genentech, Adgero Biopharmaceuticals, Myriad Genetics, Pfizer, AstraZeneca, Rhenium Medical Michael R. CragerEmployment: Exact SciencesStock and Other Ownership Interests: Exact SciencesTravel, Accommodations, Expenses: Genomic Health Robert J. GrayResearch Funding: Agios, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Genentech/Roche, Genomic Health, Genzyme, GlaxoSmithKline, Janssen-Ortho, Onyx, Pfizer, Sequenta, Syndax, Novartis, Takeda, Abbvie, Sanofi, Merck Sharp & Dohme Salomon M. StemmerStock and Other Ownership Interests: Canfite, Tyrnovo, CTG Pharma, VYPE, DocBoxMDResearch Funding: Teva, Clovis Oncology, AstraZeneca, Can-Fite BioPharma, Puma Biotechnology, Lilly, Geicam, Bristol-Myers Squibb, Roche, MSD, Halozyme, BiolineRx, Incyte, Silenseed, Tiziana Life Sciences, CTG Pharma, Syncore, Moderna Therapeutics, Exelixis, Rafael PharmaceuticalsPatents, Royalties, Other Intellectual Property: Combo patent, check point inhibitors, CTG, VYPE Steven ShakEmployment: Exact SciencesLeadership: Exact SciencesStock and Other Ownership Interests: Exact SciencesPatents, Royalties, Other Intellectual Property: Filed Oncotype DX patentsNo other potential conflicts of interest were reported.

Comment on

References

    1. Ando K, Shimomura A, Yoshimura K, et al. What is the optimal model to estimate the benefits of chemotherapy in patients with hormone receptor–positive, HER2-negative, node-negative breast cancer? J Clin Oncol 39:1946–19472021 - PubMed
    1. Sparano JA, Crager MR, Tang G, et al. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer J Clin Oncol 39557–5642021 - PMC - PubMed
    1. Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors J Clin Oncol 294365–43722011 - PMC - PubMed
    1. Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the TAILORx randomized clinical trial JAMA Oncol 6367–3742020 - PMC - PubMed
    1. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 352930–9421998 - PubMed

LinkOut - more resources